Professor discovers way to slow the growth of malignant melanoma

Victor Tron, head of pathology and molecular medicine, focused on miR-193b when he discovered that it was deficient in melanoma tumors and because there were very few studies done about the gene. The miRNA-193b gene is found in people's DNA and was unknown until 10 years ago.

“Our experiment was a bit of a fishing expedition in the beginning. We thought 193b might be important but the fact we got such a tremendous reaction – the melanoma really slowed down when we added 193b – was really startling,” says Dr. Tron, who worked with eight other Queen's researchers. “It's a totally new discovery.”

In experiments, increased levels of miR-193b increased in melanoma cells led to lower levels of a well-known protein called cyclin D1, and decreased melanoma cell growth.

Lab experiments with tissue samples proved that miR-193b plays a role in the melanoma process. Further studies will be needed to find out what causes miR-193b levels to go up and down.

“This is the first step in a long road towards finding a melanoma cure,” says Professor Tron.

Melanoma is one of the least common forms of skin cancer, yet causes 75 per cent of skin cancer deaths.

The study was recently published in the American Journal of Pathology. Pathology researchers Harriet Feilotter, Genevieve Pare, Xiao Zhang, Joshua Pemberton, Cherif Grady, Dulcie Lai and Xiaolong Yang and graduate student Jiamin Chen were also on the research team.

Queen's University is located in Kingston, Ontario Canada.

Media Contact

Michael Onesi EurekAlert!

More Information:

http://www.queensu.ca

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

After 25 years, researchers uncover genetic cause of rare neurological disease

Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…

Lower dose of mpox vaccine is safe

… and generates six-week antibody response equivalent to standard regimen. Study highlights need for defined markers of mpox immunity to inform public health use. A dose-sparing intradermal mpox vaccination regimen…

Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids

EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…

Partners & Sponsors